Efficacy and Safety of Fexinidazole in Patients With Stage 1 or Early Stage 2 Human African Trypanosomiasis (HAT) Due to T.b. Gambiense: a Prospective, Multicentre, Open-label Cohort Study, plug-in to the Pivotal Study

Trial Profile

Efficacy and Safety of Fexinidazole in Patients With Stage 1 or Early Stage 2 Human African Trypanosomiasis (HAT) Due to T.b. Gambiense: a Prospective, Multicentre, Open-label Cohort Study, plug-in to the Pivotal Study

Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 11 Oct 2016

At a glance

  • Drugs Fexinidazole (Primary)
  • Indications Trypanosomiasis
  • Focus Therapeutic Use
  • Sponsors Drugs for Neglected Diseases Initiative Foundation
  • Most Recent Events

    • 06 Oct 2016 Planned End Date changed from 1 Dec 2015 to 1 Apr 2017.
    • 06 Oct 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Oct 2016.
    • 06 Oct 2016 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top